Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
Hidetoshi KawaguchiN MasudaT NakayamaK AogiK AnanY ItoS OhtaniN SatoS SajiE TokunagaS NakamuraY HasegawaM HattoriT FujisawaS MoritaM YamaguchiT YamashitaY YamamotoS OhnoM ToiPublished in: Breast cancer research and treatment (2017)
Our study showed that treatment period of F500 was longer when used in earlier-line treatment. For patients on F500, TTF was also longer for patients who had not received prior palliative chemotherapy and for those who had a longer period from their AMBC diagnosis to F500 use.